Generic Name and Formulations:
Ticagrelor 60mg, 90mg; tabs.
Indications for BRILINTA:
To reduce the rate of cardiovascular death, MI, and stroke in patients with acute coronary syndrome (ACS) or history of MI. To reduce the rate of stent thrombosis in patients who have been stented for ACS.
Swallow whole; if unable to swallow, may crush tabs, then mix with water and drink or give via NG tube (CH8 or greater). Initially 180mg loading dose, continue with 90mg twice daily during the first year; after one year, give 60mg twice daily. After the initial loading dose of aspirin, take ticagrelor with maintenance dose of aspirin 75–100mg daily.
History of intracranial hemorrhage. Active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).
Increased risk of bleeding. Do not start in patients planned to undergo urgent CABG. Premature discontinuation increases risk for CV events (eg, MI, stroke, death). Avoid interruption of treatment; if temporarily discontinued, restart as soon as possible. When possible, interrupt therapy for 5 days prior to surgery (those with major bleeding risk); resume upon hemostasis. Effectiveness reduced with aspirin maintenance dose >100mg; avoid. History of sick sinus syndrome, 2nd or 3rd-degree AV block or bradycardia-related syncope without a pacemaker: increased risk of bradyarrhythmias. Moderate hepatic impairment. Severe hepatic impairment: avoid. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant other oral P2Y12 platelet inhibitor: not recommended. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, telithromycin) or potent CYP3A inducers (eg, rifampin, phenytoin, carbamazepine, phenobarbital). Potentiates simvastatin, lovastatin; avoid >40mg/day doses. Monitor digoxin during ticagrelor initiation and dose adjustments.
P2Y12 platelet inhibitor (cyclopentyltriazolopyrimidine).
Bleeding (may be fatal), dyspnea (consider other alternatives if intolerable), dizziness, nausea, diarrhea; ventricular pauses.
Tabs 60mg—60; 90mg—14, 60
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML